Navigation Links
Updated MD-CARE Act Receives Final Congressional Approval
Date:9/27/2008

TUCSON, Ariz., Sept. 27 /PRNewswire-USNewswire/ -- The Paul D. Wellstone Muscular Dystrophy Community Assistance, Research and Education (MD-CARE) Amendments of 2008 received final Congressional approval today. It now goes to President Bush, who is expected to sign it.

The approved legislation -- which reauthorizes and updates the MD-CARE Act of 2001 -- will escalate research and the development of treatments for several forms of muscular dystrophy.

Dr. R. Rodney Howell, the Muscular Dystrophy Association's chairman of the board, was pleased with the Congressional action, noting, "MDA is proud to stand with Congress and thousands of MD advocates to take this significant step toward increased clinical trials and therapies for muscular dystrophy. The MD-CARE Act's newly reauthorized commitment to funding research and clinical excellence ensures continued progress towards a cure."

Howell gratefully acknowledged the efforts and commitment of the legislators who sponsored the amended MD-CARE Act: Congressmen Eliot Engel (D-NY) and Michael Burgess (R-TX) [H.R. 5265] and Senators Amy Klobuchar (D-MN) and Johnny Isakson (R-GA) [S. 2618].

The MD-CARE Act of 2001 required that the National Institutes of Health (NIH) designate muscular dystrophy Research Centers of Excellence to work independently and collaboratively on clinical research projects dealing with muscular dystrophy.

MDA aided creation of the centers by contributing $1.5 million to each of the first three.

The original MD-CARE Act also mandated creation of a Muscular Dystrophy Coordinating Committee to expand and intensify research efforts, established an epidemiological data collection system under the auspices of the federal Centers for Disease Control, and piloted a national care considerations project for the treatment of Duchenne and Becker muscular dystrophies.

The newly passed MD-CARE Amendments include several new provisions:

-- Expand the NIH Institutes involved to include the National Heart, Lung and Blood Institute.

-- Officially name the centers of excellence, the Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers, after the late Senator who served as a champion for the MD community.

-- The epidemiological data system may be expanded to include health outcomes and reflect patients' changing conditions over time.

-- The development and broad dissemination of care considerations for the muscular dystrophies.

-- As promising therapies for muscular dystrophies are identified, they are eligible to be processed through an enhanced clinical infrastructure that "fast tracks" research findings into viable therapies for patients.

MDA is a voluntary health agency supporting programs of worldwide research, comprehensive services and far-reaching professional and public health education for muscular dystrophy and related diseases. The Association's programs are funded almost entirely by individual private contributors.


'/>"/>
SOURCE Muscular Dystrophy Association
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Updated GOLD report presents new understandings in diagnosis, treatment and prevention of COPD
2. Updated Brochure on Gynecologic Cancer Treatments Now Available
3. Medifast Announces Updated Full Year 2007 Guidance
4. Updated: National Infertility Awareness Week Nov. 4-10; Infertility Affects Significant Number of Couples
5. Long-term pharmacotherapy for obesity and overweight: updated meta-analysis
6. inVentiv Health Provides Updated Information on December 11th Investor Day
7. UPDATED: Evalve(R) Completes $60 Million Series D Financing
8. Updated Analysis of 2001 Epoetin Alfa Study Posted
9. American College of Gastroenterology Offers Updated Clinical Guidance for Managing Pregnant Patients
10. Adult stem cell heart attack study updated at American Society for Hematology Meeting
11. CAHI Releases Updated Health Insurance Mandates in the States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... , ... “When the Stars Lead Home”: a poignant story of loss, determination, ... Weigel Douglas, an avid reader who lives in the Pacific Northwest with her husband, ... Hills Adventure Camp. She couldn’t be more grateful. , Twelve-year old Tizzy could not ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... recipient of proceeds from its 14th Annual Clays for Kids fundraiser, to be ... 30, Bennett, Colorado. , As part of BluSky’s partnership with The Adoption ...
(Date:5/26/2017)... ... ... “Cactus Jack: Against All Odds”: the story of Coach Cactus Jack and ... Odds” is the creation of published author, Walter Hubbard, a retired wildlife and fisheries ... child Jane. Walter. Walter and Jane have three adult children and a granddaughter. ...
(Date:5/24/2017)... BELLEVILLE, N.J. (PRWEB) , ... May 24, 2017 ... ... joined Clara Maass Medical Center CEO Mary Ellen, hospital employees, and town officials ... in Belleville. , The facility was developed by Rendina as part of its ...
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. Alan I. Benvenisty, MD ... New York City. He is known for his distinguished expertise and experience in the ... Benvenisty holds sub-specialty training in treating renovascular disease and aortic aneurysm . He ...
Breaking Medicine News(10 mins):
(Date:5/26/2017)... , May 25, 2017  In response to ... , Direct Relief is working with Pfizer to ... available at no cost to community health centers, free ... providers nationwide. "Pfizer has a long-standing ... medicines and ensuring patient safety through educational activities," said ...
(Date:5/22/2017)... 2017  Lilac Corp, the company that sells ... of a new website . The website ... clinical study that showed surprising clearance of the ... individuals suffering from HPV warts, precancerous, or cancerous ... no other treatments that clear the virus. Specifically, ...
(Date:5/18/2017)... May 17, 2017  Bayer announced today that the ... be presented at the 53 rd Annual Meeting ... place June 2-6 in Chicago . ... span prostate, colorectal, liver and thyroid cancers, as well ... Phase II CHRONOS-1 trial of copanlisib in patients with ...
Breaking Medicine Technology: